Implications of applied research for prognosis and therapy of breast cancer

被引：5

作者：

Barginear, M. F. ^{[1
]}

Bradley, T. ^{[1
]}

Shapira, I. ^{[1
]}

Budman, D. R. ^{[1
]}

机构：

[1] CUNY, Sch Med, N Shore Univ Hosp, Don Monti Div Med Oncol Div Hematol, New York, NY USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2008年 / 65卷 / 03期

关键词：

breast cancer; molecular profiling; gene expression profiles;

D O I：

10.1016/j.critrevonc.2007.11.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is the one of leading causes of cancer-related deaths in women within economically developed regions of the world. The heterogeneity of the natural history of breast cancer complicates patient management in that there is tremendous variability in response to treatment and for survival. More recently, several biomarkers (hormone receptor status and HER2 expression) have been added to the risk evaluation and therapeutic assessments. Evolving knowledge of molecular biology and newer techniques, such as genomics and proteomics, offer the potential to better define the biologic nature of the disease process, both for risk and therapy. This review discusses classical as well as new prognostic and predictive techniques. These are leading to a paradigm shift from empirical treatment to an individually tailored approach, which may soon become a realistic option for patients, based on specific molecular profiles. (c) 2007 Elsevier Ireland Ltd. All fights reserved.

引用

页码：223 / 234

页数：12

共 146 条

[71] Tumor oxygenation correlates with molecular growth determinants in breast cancer [J].

Hohenberger, P ;

Felgner, C ;

Haensch, W ;

Schlag, PM .

BREAST CANCER RESEARCH AND TREATMENT, 1998, 48 (02) :97-106

[72] PREDICTING RESPONSE TO ENDOCRINE THERAPY IN HUMAN BREAST-CANCER - HYPOTHESIS [J].

HORWITZ, KB ;

MCGUIRE, WL ;

PEARSON, OH ;

SEGALOFF, A .

SCIENCE, 1975, 189 (4204) :726-727

[73] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer [J].

Howell, A ;

Cuzick, J ;

Baum, M ;

Buzdar, A ;

Dowsett, M ;

Forbes, JF ;

Hoctin-Boes, G ;

Houghton, I ;

Locker, GY ;

Tobias, JS .

LANCET, 2005, 365 (9453) :60-62

[74] Proteomic analysis in human breast cancer: Identification of a characteristic protein expression profile of malignant breast epithelium [J].

Hudelist, G ;

Singer, CF ;

Pischinger, KID ;

Kaserer, K ;

Manavi, M ;

Kubista, E ;

Czerwenka, KF .

PROTEOMICS, 2006, 6 (06) :1989-2002

[75] CLINICAL RELEVANCE OF THE UROKINASE-TYPE AND TISSUE-TYPE PLASMINOGEN ACTIVATORS AND OF THEIR TYPE-1 INHIBITOR IN BREAST-CANCER [J].

JANICKE, F ;

SCHMITT, M ;

GRAEFF, H .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1991, 17 (03) :303-312

[76] Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling [J].

Jansen, MPHM ;

Foekens, JA ;

van Staveren, IL ;

Dirkzwager-Kiel, MM ;

Ritstier, K ;

Look, MP ;

Meijer-van Gelder, ME ;

Sieuwerts, AM ;

Portengen, H ;

Dorssers, LCJ ;

Klijn, JGM ;

Berns, EMJJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :732-740

[77] Hazard rates of recurrence following diagnosis of primary breast cancer [J].

Jatoi, I ;

Tsimelzon, A ;

Weiss, H ;

Clark, GM ;

Hilsenbeck, SG .

BREAST CANCER RESEARCH AND TREATMENT, 2005, 89 (02) :173-178

[78] Cancer statistics, 2007 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Murray, Taylor ;

Xu, Jiaquan ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66

[79]

JENSEN EV, 1971, NATL CANCER I MONOGR, P55

[80] Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy [J].

Kreike, Bas ;

Halfwerk, Hans ;

Kristel, Petra ;

Glas, Annuska ;

Peterse, Hans ;

Bartelink, Harry ;

van de Vijver, Marc J. .

CLINICAL CANCER RESEARCH, 2006, 12 (19) :5705-5712

← 3 4 5 6 7 8 9 10 11 12 →